Table 3. IC₅₀ Values (μM) Determined by the MTT Test after 72 h of Treatment^a.

	MCF-7	HeLa	518A2	HCT116	RD	MRC5pd30	SIb
1	2.4 ± 0.6	4.0 ± 0.4	2.6 ± 0.4	1.5 ± 0.1	2.2 ± 0.2	5.8 ± 0.7	2.3
2	32 ± 4	53 ± 4	26 ± 4	25 ± 2	26 ± 5	76 ± 1	2.4
3	38 ± 8	91 ± 3	33 ± 5	25 ± 1	27 ± 4	83.6 ± 0.5	2.0
4	37 ± 7	36 ± 1	35 ± 4	25 ± 2	25 ± 3	56.6 ± 0.7	1.8
5	32 ± 5	54 ± 6	31 ± 3	30 ± 2	23 ± 2	63 ± 4	1.9
6	46 ± 7	54 ± 14	38 ± 8	31 ± 2	38 ± 6	82 ± 4	2.0
7	6 ± 1	10 ± 2	6.8 ± 0.8	6.7 ± 0.4	6 ± 1	24 ± 1	3.4
8	10 ± 2	15 ± 1	10 ± 2	8 ± 2	6.6 ± 0.7	19.7 ± 0.4	2.0
9	43 ± 7	36 ± 2	38 ± 7	35 ± 6	24 ± 3	50.8 ± 0.4	1.5
cisplatin	13 ± 3c	14 ± 3c	2.6 ± 0.7d	8 ± 1c	4.6 ± 0.3	11.7 ± 0.8c	1.1

^aThe results are expressed as mean values ± SD from at least three independent experiments.

^bSelectivity index (SI) was calculated as IC₅₀ for noncancerous MRC-5pd30 vs the average IC₅₀ value of cancer cell lines.

^cData taken from ref (63).

^dData taken from ref (64).